The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.48 (26.812%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Mining stocks pull FTSE 100 lower ahead of data

Thu, 12th Jun 2014 08:25

- Profit taking continues as miners fall- Traders await global economic data- Broker downgrades hit blue chipstechMARK 2,839.63 -0.04%FTSE 100 6,827.09 -0.17%FTSE 250 16,073.58 -0.09%UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound.After coming within reach of a 14-year closing high earlier in the week, the FTSE 100 suffered a steep fall on Wednesday to finish at 6,838.87. Investors were looking to book profits with global equity indices trading at multi-year or record highs, while sentiment was dampened further after the World Bank downgraded its growth forecasts.Subdued risk appetite was keeping investors from 'buying on the dip' this morning as they awaited what is set to be a somewhat heavier session in terms of macro data. The FTSE 100 was 0.2% lower at 6,827 in early trading.Mike van Dulken, Head of Research at Accendo Markets, said that after the recent run on major bourses, traders are now "concerned about complacency and the emergence of fresh risks following a period of relative calm". Nevertheless, the FTSE 100 still remains range-bound with "catalysts lacking (for now) for a break either way", he said.After a quiet start to the week on the economic calendar, the focus today will turn to Eurozone industrial production, French inflation and US retail sales and jobless claims figures.Mining stocks fallMiners were among the worst performers this morning with Anglo American, BHP Billiton, Rio Tinto and Antofagasta falling sharply. Anglo was cut from 'equal weight' to 'underweight' at Morgan Stanley today.Shares in AstraZeneca rose after the pharmaceutical group signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma.Natural gas producer BG Group was lower as it suffered from a ratings downgrade by Nomura to 'neutral'. Publisher Pearson was subdued after a Goldman Sachs downgrade to 'sell', while temporary power and temperature control group Aggreko was hit with a downgrade to 'sector performer' by RBC Capital Markets.In contrast, Provident Financial was on the rise after Citigroup lifted its recommendation on the stock to 'buy' and hiked its target price by nearly 38%.Infrastructure and construction peers Balfour Beatty, Galliford Try and Carillion all fell despite the news that they have been appointed as preferred bidders to work on a £745m project to build new roads in Scotland.Halma impressed with record annual revenue as the safety, health and environmental technology group achieved growth across all its sectors.Home improvement retailer Kingfisher edged lower after revealing that Philippe Tible, Chief Executive of its European Castorama & Brico Depot brands, will step down from the board at the end of July.FTSE 100 - RisersITV (ITV) 179.60p +1.70%Unilever (ULVR) 2,700.00p +0.82%AstraZeneca (AZN) 4,434.00p +0.77%British American Tobacco (BATS) 3,564.00p +0.59%Reckitt Benckiser Group (RB.) 5,155.00p +0.59%Lloyds Banking Group (LLOY) 79.51p +0.57%Imperial Tobacco Group (IMT) 2,640.00p +0.46%Diageo (DGE) 1,915.50p +0.45%Rolls-Royce Holdings (RR.) 1,021.00p +0.39%GlaxoSmithKline (GSK) 1,617.50p +0.37%FTSE 100 - FallersAnglo American (AAL) 1,410.50p -3.69%Rio Tinto (RIO) 3,093.00p -2.01%BHP Billiton (BLT) 1,856.50p -1.90%Aggreko (AGK) 1,628.00p -1.75%Sainsbury (J) (SBRY) 327.90p -1.53%International Consolidated Airlines Group SA (CDI) (IAG) 394.10p -1.48%Antofagasta (ANTO) 760.00p -1.23%Fresnillo (FRES) 783.50p -1.14%Glencore (GLEN) 320.60p -1.11%ARM Holdings (ARM) 898.00p -1.05%FTSE 250 - RisersOcado Group (OCDO) 380.00p +3.43%Provident Financial (PFG) 2,221.00p +2.26%Halma (HLMA) 602.50p +1.95%Partnership Assurance Group (PA.) 132.20p +1.85%Premier Farnell (PFL) 212.20p +1.82%Perform Group (PER) 274.50p +1.63%Fisher (James) & Sons (FSJ) 1,330.00p +1.53%Alent (ALNT) 335.00p +1.52%PayPoint (PAY) 1,131.00p +1.25%Infinis Energy (INFI) 211.60p +1.24%FTSE 250 - FallersAfren (AFR) 140.90p -2.29%Lonmin (LMI) 232.40p -1.82%Synthomer (SYNT) 244.97p -1.81%African Barrick Gold (ABG) 219.30p -1.75%Polymetal International (POLY) 545.50p -1.71%Evraz (EVR) 97.90p -1.66%Victrex plc (VCT) 1,737.00p -1.64%Ophir Energy (OPHR) 237.00p -1.62%Serco Group (SRP) 364.80p -1.33%Aveva Group (AVV) 2,217.00p -1.25%BC
More News
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.